Literature DB >> 22371634

Routine blood tests to predict liver fibrosis in chronic hepatitis C.

Yung-Yu Hsieh1, Shui-Yi Tung, Kamfai Lee, Cheng-Shyong Wu, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Yi-Hsiung Lin.   

Abstract

AIM: To verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C, compared with other noninvasive tests.
METHODS: This retrospective cohort study included 237 consecutive patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treatment. FibroQ, aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR), AST to platelet ratio index, cirrhosis discriminant score, age-platelet index (API), Pohl score, FIB-4 index, and Lok's model were calculated and compared.
RESULTS: FibroQ, FIB-4, AAR, API and Lok's model results increased significantly as fibrosis advanced (analysis of variance test: P < 0.001). FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests.
CONCLUSION: FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.

Entities:  

Keywords:  Alanine aminotransferase; Aspartate aminotransferase; Aspartate aminotransferase to platelet ratio index; Cirrhosis discriminant score; FIB-4 index; FibroQ; Liver fibrosis; Lok’s model; Noninvasive test; Pohl score

Mesh:

Year:  2012        PMID: 22371634      PMCID: PMC3286137          DOI: 10.3748/wjg.v18.i8.746

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 2.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 3.  Treatment of patients with chronic hepatitis C and cirrhosis.

Authors:  F Bonino; F Oliveri; P Colombatto; B Coco; D Mura; G Realdi; M R Brunetto
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

4.  Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection.

Authors:  A Pohl; C Behling; D Oliver; M Kilani; P Monson; T Hassanein
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

5.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection.

Authors:  Arie Regev; Mariana Berho; Lennox J Jeffers; Clara Milikowski; Enrique G Molina; Nikolaos T Pyrsopoulos; Zheng-Zhou Feng; K Rajender Reddy; Eugene R Schiff
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

6.  Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

Authors:  Enrico Rossi; Leon Adams; Alexander Prins; Max Bulsara; Bastiaan de Boer; George Garas; Gerry MacQuillan; David Speers; Gary Jeffrey
Journal:  Clin Chem       Date:  2003-03       Impact factor: 8.327

7.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

8.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.

Authors:  Guido Colloredo; Maria Guido; Aurelio Sonzogni; Gioacchino Leandro
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

9.  Clinical significance of activity of ALT enzyme in patients with hepatitis C virus.

Authors:  Onder Akkaya; Murat Kiyici; Yusuf Yilmaz; Engin Ulukaya; Omer Yerci
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

10.  Sampling variability of liver fibrosis in chronic hepatitis C.

Authors:  Pierre Bedossa; Delphine Dargère; Valerie Paradis
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

View more
  9 in total

1.  A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.

Authors:  G Shiha; S Seif; A Eldesoky; M Elbasiony; R Soliman; A Metwally; K Zalata; N Mikhail
Journal:  Hepatol Int       Date:  2017-04-19       Impact factor: 6.047

2.  Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.

Authors:  James F Crismale; Valérie Martel-Laferrière; Kian Bichoupan; Emily Schonfeld; Alexis Pappas; Christina Wyatt; Joseph A Odin; Lawrence U Liu; Thomas D Schiano; Ponni V Perumalswami; Meena Bansal; Douglas T Dieterich; Andrea D Branch
Journal:  Liver Int       Date:  2013-10-25       Impact factor: 5.828

Review 3.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Non-invasive serum fibrosis markers: A study in chronic hepatitis.

Authors:  Mohammadreza Abdollahi; Aliasghar Pouri; Morteza Ghojazadeh; Rasoul Estakhri; Mohammadhossein Somi
Journal:  Bioimpacts       Date:  2015-02-22

5.  Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.

Authors:  Shelley S Selph; Alexander D Ginsburg; Roger Chou
Journal:  Syst Rev       Date:  2014-09-19

6.  Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

Authors:  Roberta D'Ambrosio; Elisabetta Degasperi; Alessio Aghemo; Mirella Fraquelli; Pietro Lampertico; Maria Grazia Rumi; Floriana Facchetti; Eleonora Grassi; Giovanni Casazza; William Rosenberg; Pierre Bedossa; Massimo Colombo
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

7.  Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C.

Authors:  Joanna Gorka-Dynysiewicz; Monika Pazgan-Simon; Jolanta Zuwala-Jagiello
Journal:  Biomed Res Int       Date:  2019-04-02       Impact factor: 3.411

8.  Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.

Authors:  Mette J Nielsen; Konstantin Kazankov; Diana J Leeming; Morten A Karsdal; Aleksander Krag; Francisco Barrera; Duncan McLeod; Jacob George; Henning Grønbæk
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

9.  Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases.

Authors:  Monika Gudowska; Alicja Wrona; Ewa Gruszewska; Anatol Panasiuk; Bogdan Cylwik; Magdalena Swiderska; Robert Filisiak; Maciej Szmitkowski; Lech Chrostek
Journal:  Clin Exp Hepatol       Date:  2016-11-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.